Board of Directors

Robert

Dr. Robert S. Schwartz

Dr. Robert S. Schwartz

Co-Founder

Interventional Cardiologist & Inventor Co-Founder of CorFlow Therapeutics AG, Medical Director of Education, Minnesota Cardiovascular Research Institute and Senior Consulting Cardiologist, Minneapolis Heart Institute, Minneapolis, MN, USA Rob is a practising interventional cardiologist and a prolific inventor who over the last decades has been granted numerous medical device patents. He has been instrumental to found companies such as Osprey Medical and Autonomix and has a passion to solve the no-reflow problem for acute heart attack patients.

Martin

Prof. Martin T. Rothman

Prof. Martin T. Rothman

Co-Founder

Cardiologist & VP Medical Affairs Medtronic Co-Founder of CorFlow Therapeutics AG, Chief Medical Officer and VP of Medical Affairs, Medtronic Coronary, RDN & Structural Heart, Santa Rosa, CA, USA, Honorary Professor of Interventional Cardiology, Queen Mary, University of London, United Kingdom Martin is a world-renown and NHS pioneer in interventional cardiology and has founded numerous cardiology medical device companies raising more than £300M for these early stage companies. He joined Medtronic in 2010 and is now responsible for a wide product spectrum from coronary&vascular disease to resistant hypertension and minimally invasive heart valves.

Gunnar

Gunnar M. Páh

Gunnar M. Páh

Gunnar has over 40 year’s experience in medical device distribution, start-ups and financing. He started as a sales manager in Medico (Oslo, Norway) and has founded successful distribution companies in Europe (Medi-Stim AS (1984), CardioMed GmbH (1994) and MicroMed (1994)). Gunnar is an active early stage investor in several breakthrough interventional cardiology companies of which many have had a successful exit: AVE, Vascular Science, Atritech, Embolic Protection, Rubicon, Sapheon, Loma Vista, CoreValve and CardiAQ.

Erik

Erik Amble

Erik Amble

Erik is the chairman and founder of NeoMed Management and was previously the chairman and controlling shareholder of NeoMed AS, providing investment advisory services, specializing in small and medium sized companies in the pharmaceutical, medical device and diagnostic industries. Erik has served as a board member of a. o. Clavis Pharma AS (which went public on the Oslo Stock Exchange), GenoVision AS (sold to Qiagen), Thommen Medical AG (investment sold in a private secondary sale) and Vessix Vascular Inc. (sold to Boston Scientific Corporation), and currently serves on the Board of Directors of Axonics Modulation Technologies Inc. (USA), JenaValve Technology Inc. (USA, Germany), Sequana Medical AG (Switzerland) and Sonendo Inc. (USA). Erik is a founder and former chairman of the Norwegian Venture Capital Association. He holds a Dr. Scient. degree in organic chemistry from the University of Oslo and a Master of Science degree in Management from the Graduate School of Business, Stanford University, USA.

Tim

Tim Snyder

Tim Snyder

In addition to his role as Chief Financial Officer, Tim is currently serving as the company’s interim Chairman of the Board of Directors. Tim joined CorFlow in 2018 with 30 years’ experience in financial leadership roles. He started his career at Deloitte in Columbus, Ohio (USA). After nine years as a practicing CPA, he went on to serve as Finance Director and CFO for a number of international companies in the United States and Europe. Besides accounting and finance, Tim has extensive experience in business combinations, stock exchange regulations, and corporate governance. Tim holds a degree in Business Administration from The Ohio State University.